Papzimeos is the first and only FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP), with ...

To help Medicare plans better manage members with high drug expenses, Prime Therapeutics has launched an AI-driven tool to ...

Those with hemophilia face heightened risks of depression and anxiety due to pain and joint issues, impacting their overall ...

IO Biotech plans to meet with the FDA this fall to discuss the data from the phase 3 trial of Cylembio and determine next ...

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive (MHE) editorial advisory board, is host of the ...

According to the American Cancer Society, about 22,000 new esophageal cancer cases were diagnosed in 2025 in the U.S., and ...

This final part of the three-part video series highlights Sharon Faust of Navitus reflecting on how personal challenges, including her husband’s accident, reshaped her perspective and empowered her to ...

The UC Davis team is studying a less invasive way of delivering gene therapy to the eye: injecting the gene therapy into the suprachoroidal space, a tiny layer between the white of the eye and the ...

Switching to rFVIIIFc significantly reduces bleeding rates and injection frequency for hemophilia A patients, enhancing ...

HIV-fighting antibodies produced in infant macaques in a preclinical trial could be the future of HIV prevention in humans, ...

Children with HIV face a shortened life span, educational barriers and daily stigma, according to Amir Ardeshir, Ph.D., DVM, associate professor of microbiology and immunology at Tulane University.

The FDA has granted accelerated approval to Hernexeos (zongertinib), making it the first oral targeted therapy for previously treated adults with advanced lung cancer driven by HER2 mutations. HER2 ...